University of Pennsylvania investigators and clinicians discussed the Philadelphia “Baby KJ” CRISPR base-editing case study, characterizing it as a single-patient expanded access effort rather than a conventional cure-focused trial. Lead investigator Kiran Musunuru said the intervention demonstrated what is possible under an expanded access IND and emphasized that regulators must be able to keep pace with genome editing’s rapid evolution. The discussion also places the case in the context of a broader CRISPR base-editing push, with companies including Verve Therapeutics and YolTech Therapeutics pursuing clinical trials. Musunuru’s comments underscore the expectation that future programs will need tightly framed evidence packages beyond landmark individual cases.